$SNDX
Syndax Pharmaceuticals Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023037943 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.30M $14.90M
YoY Change 109.95% 86.48%
% of Gross Profit
Research & Development $39.09M $34.76M
YoY Change 45.3% 16.92%
% of Gross Profit
Depreciation & Amortization $0.00 $3.000K
YoY Change -100.0% -72.73%
% of Gross Profit
Operating Expenses $56.36M $49.68M
YoY Change 60.37% 31.69%
Operating Profit -$56.36M -$49.68M
YoY Change 60.37% 31.69%
Interest Expense $70.00K $35.00K
YoY Change -96.0% -94.96%
% of Operating Profit
Other Income/Expense, Net $5.209M $5.063M
YoY Change -2088.17% 3230.92%
Pretax Income -$51.10M -$44.60M
YoY Change 44.34% 18.71%
Income Tax
% Of Pretax Income
Net Earnings -$51.15M -$44.62M
YoY Change 44.47% 18.75%
Net Earnings / Revenue
Basic Earnings Per Share -$0.73 -$0.64
Diluted Earnings Per Share -$0.73 -$0.64
COMMON SHARES
Basic Shares Outstanding 69.48M 68.82M
Diluted Shares Outstanding 69.86M 69.64M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $373.8M $406.0M
YoY Change 6.58% 7.79%
Cash & Equivalents $94.55M $97.28M
Short-Term Investments $279.3M $308.7M
Other Short-Term Assets $3.000M $2.522M
YoY Change 51.98% 20.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $381.0M $409.1M
YoY Change 6.53% 4.28%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $1.981M
YoY Change -56.52% 673.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $15.70M $19.48M
YoY Change 60.68%
Other Assets $587.0K $796.0K
YoY Change -33.37% -20.0%
Total Long-Term Assets $18.25M $22.26M
YoY Change 787.65% 57.31%
TOTAL ASSETS
Total Short-Term Assets $381.0M $409.1M
Total Long-Term Assets $18.25M $22.26M
Total Assets $399.2M $431.3M
YoY Change 10.99% 6.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.049M $10.98M
YoY Change -14.98% 70.52%
Accrued Expenses $33.10M $18.69M
YoY Change 141.89% 8.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $11.00K
YoY Change -100.0% -99.85%
Total Short-Term Liabilities $39.17M $30.17M
YoY Change 88.31% -2.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $16.00K
YoY Change -100.0% -99.88%
Other Long-Term Liabilities $900.0K $1.115M
YoY Change 17.19% 95.61%
Total Long-Term Liabilities $864.0K $1.131M
YoY Change 10.49% -91.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.17M $30.17M
Total Long-Term Liabilities $864.0K $1.131M
Total Liabilities $40.04M $31.30M
YoY Change 85.49% -29.66%
SHAREHOLDERS EQUITY
Retained Earnings -$829.9M -$778.8M
YoY Change 26.93% 25.93%
Common Stock $1.190B $1.179B
YoY Change 19.73% 20.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $359.2M $400.0M
YoY Change
Total Liabilities & Shareholders Equity $399.2M $431.3M
YoY Change 10.99% 6.13%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$51.15M -$44.62M
YoY Change 44.47% 18.75%
Depreciation, Depletion And Amortization $0.00 $3.000K
YoY Change -100.0% -72.73%
Cash From Operating Activities -$44.65M -$35.37M
YoY Change 56.43% -12.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $40.08M $73.91M
YoY Change -690.02% -247.97%
Cash From Investing Activities $40.08M $73.91M
YoY Change -690.02% -247.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.850M 1.324M
YoY Change -113.68% -93.9%
NET CHANGE
Cash From Operating Activities -44.65M -35.37M
Cash From Investing Activities 40.08M 73.91M
Cash From Financing Activities 1.850M 1.324M
Net Change In Cash -2.720M 39.86M
YoY Change -94.43% -158.16%
FREE CASH FLOW
Cash From Operating Activities -$44.65M -$35.37M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
dei Entity Central Index Key
EntityCentralIndexKey
0001395937
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37708
dei Entity Registrant Name
EntityRegistrantName
Syndax Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
419-1400
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SNDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69484053
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97275000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74356000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
301526000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
401446000
CY2023Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
7223000
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
8595000
CY2023Q2 sndx Collaboration Receivable
CollaborationReceivable
0
CY2022Q4 sndx Collaboration Receivable
CollaborationReceivable
3474000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3056000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1915000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
409080000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
489786000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
19483000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
5469000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1968000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1039000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
217000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
115000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
579000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
807000
CY2023Q2 us-gaap Assets
Assets
431340000
CY2022Q4 us-gaap Assets
Assets
497236000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10978000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4350000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17729000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24276000
CY2023Q2 sndx Collaboration Payable Current
CollaborationPayableCurrent
493000
CY2022Q4 sndx Collaboration Payable Current
CollaborationPayableCurrent
0
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
957000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
434000
CY2023Q2 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
11000
CY2022Q4 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
5000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30168000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29065000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1115000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
709000
CY2023Q2 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
16000
CY2022Q4 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
13000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1131000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
722000
CY2023Q2 us-gaap Liabilities
Liabilities
31299000
CY2022Q4 us-gaap Liabilities
Liabilities
29787000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69431198
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69431198
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68111385
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68111385
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1179389000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1161288000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-574000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-806000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-778781000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-693040000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
400041000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
431340000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497236000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34764000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29734000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68819000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59756000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14914000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7990000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26875000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14827000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
49678000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
37724000
us-gaap Operating Expenses
OperatingExpenses
95694000
us-gaap Operating Expenses
OperatingExpenses
74583000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-49678000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37724000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95694000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74583000
CY2023Q2 us-gaap Interest Expense
InterestExpense
35000
CY2022Q2 us-gaap Interest Expense
InterestExpense
695000
us-gaap Interest Expense
InterestExpense
75000
us-gaap Interest Expense
InterestExpense
1346000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5191000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
878000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10268000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1103000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
209000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
311000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
187000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-93000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-240000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5063000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
152000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9953000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-158000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44615000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
us-gaap Net Income Loss
NetIncomeLoss
-85741000
us-gaap Net Income Loss
NetIncomeLoss
-74741000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-238000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
232000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1380000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44853000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38267000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85509000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76121000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44615000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37572000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85741000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74741000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69638427
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69638427
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60156653
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60156653
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69539209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69539209
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59570888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59570888
us-gaap Profit Loss
ProfitLoss
-85741000
us-gaap Profit Loss
ProfitLoss
-74741000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
6000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
22000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7685000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
320000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
259000
us-gaap Share Based Compensation
ShareBasedCompensation
14303000
us-gaap Share Based Compensation
ShareBasedCompensation
7416000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-459000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4930000
sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
3967000
sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
-13102000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6629000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
769000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6796000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2316000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74599000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82237000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
142593000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
164632000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
236415000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
122866000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
93822000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41766000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
374000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
150000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3424000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19427000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3798000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22277000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23021000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-101726000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74471000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222080000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97492000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120354000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
960000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Syndax Pharmaceuticals, Inc. (“we,” “us,” “our” or the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44615000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
us-gaap Net Income Loss
NetIncomeLoss
-85741000
us-gaap Net Income Loss
NetIncomeLoss
-74741000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44615000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-44615000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37572000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-37572000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85741000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-85741000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74741000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-74741000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69638427
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69638427
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60156653
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60156653
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69539209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69539209
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59570888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59570888
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
321583000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
574000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
321009000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
422581000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
806000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
421775000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1459000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
692000
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
534000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
583000
CY2023Q2 sndx Prepaid Subscriptions
PrepaidSubscriptions
784000
CY2022Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
446000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
279000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
194000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3056000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1915000
CY2023Q2 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
10633000
CY2022Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
14375000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5626000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5945000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
936000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1352000
CY2023Q2 sndx Accrued Milestone Costs
AccruedMilestoneCosts
0
CY2022Q4 sndx Accrued Milestone Costs
AccruedMilestoneCosts
2000000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
534000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
604000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17729000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24276000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8065000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3938000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14303000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7416000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8065000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3938000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14303000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7416000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
439543
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3400000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
286572
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2700000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6238000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
470000
CY2023Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
196000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
435505000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8065000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-238000
CY2023Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
179000
CY2023Q2 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-1000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1146000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44615000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
400041000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3478000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-685000
CY2022Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
92000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
374549000
CY2022Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
19427000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2022Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
58000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2235000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
361940000
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3802144
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81200000
CY2023Q2 sndx Number Of Pre Funded Warrants Exercised For Common Stock
NumberOfPreFundedWarrantsExercisedForCommonStock
273000
CY2023Q2 sndx Number Of Pre Funded Warrants Exercised For Common Stock
NumberOfPreFundedWarrantsExercisedForCommonStock
498137
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7840909
CY2022Q4 sndx Offering Price Per Share
OfferingPricePerShare
22.00
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162000000.0
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0
sndx Rule10 B51 Arr Trmntd Flag
Rule10B51ArrTrmntdFlag
true
sndx Rule10 B51 Arr Adopted Flag
Rule10B51ArrAdoptedFlag
true
sndx Trd Arr Ind Name
TrdArrIndName
William Meury
sndx Trd Arr Ind Title
TrdArrIndTitle
Director
sndx Trd Arr Adoption Date
TrdArrAdoptionDate
5/3/2023
sndx Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
83000
sndx Trd Arr Termination Date
TrdArrTerminationDate
4/26/2024

Files In Submission

Name View Source Status
0000950170-23-037943-index-headers.html Edgar Link pending
0000950170-23-037943-index.html Edgar Link pending
0000950170-23-037943.txt Edgar Link pending
0000950170-23-037943-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20230630.htm Edgar Link pending
sndx-20230630.xsd Edgar Link pending
sndx-ex31_1.htm Edgar Link pending
sndx-ex31_2.htm Edgar Link pending
sndx-ex32_1.htm Edgar Link pending
sndx-20230630_def.xml Edgar Link unprocessable
sndx-20230630_lab.xml Edgar Link unprocessable
sndx-20230630_pre.xml Edgar Link unprocessable
sndx-20230630_htm.xml Edgar Link completed
sndx-20230630_cal.xml Edgar Link unprocessable